Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19: A pilot randomized clinical trial (STRUCK: Survival Trial Using Cytokine Inhibitors)
Lívia Pimenta Bonifácio, Eduardo Ramacciotti, Leandro Barile Agati, Fernando Crivelenti Vilar, Anna Christina Tojal Da Silva, Paulo Louzada Júnior, Benedito Antônio Lopes Da Fonseca, Hayala Cristina Cavenague De Souza, Caroline Candida Carvalho De Oliveira, Valéria Cristina Resende Aguiar, Carlos Augusto De Aguiar Quadros, Cesar Dusilek, Kengi Itinose, Ricardo Risson, Lucas Roberto Rivabem Ferreira, Renato Delascio Lopes, Esper Georges Kallas, Dr Fernando Bellissimo-Rodrigues
Revista da Sociedade Brasileira de Medicina Tropical, doi:10.1590/0037-8682-0565-2022
data analysis; interpretation of results; critical revision of the final version for publication. FB-R -Study conception and design; study execution planning; supervision of the whole study team; interpretation of results; rewriting of the manuscript; critical analysis of the final version for publication. All authors reviewed the study, and approved the final version for publication. Authors hold themselves responsible for all aspects of the study, to ensure that all questions referring to accuracy and integrity are investigated and solved appropriately.
SUPPLEMENTARY TABLE 2: Plasma cytokine profiles (pg/mL) in COVID-19 patients at baseline (D 1) versus day 28 (D 28). SUPPLEMENTARY MATERIAL
Groups
References
Absalon-Aguilar, Rull-Gabayet, Perez-Fragoso, Mejia-Dominguez, Nunez-Alvarez et al., Colchicine Is Safe Though Ineffective in the Treatment of Severe COVID-19: a Randomized Clinical Trial (COLCHIVID), J Gen Intern Med
Angus, Derde, Al-Beidh, Annane, Arabi et al., Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial, JAMA
Avdeev, Trushenko, Tsareva, Yaroshetskiy, Merzhoeva et al., Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study, Cytokine
Beringer, Miossec, Systemic effects of IL-17 in inflammatory arthritis, Nat Rev Rheumatol
Bonifácio, Exploring new targets for COVID-19 treatment
Bryushkova, Skatova, Mutovina, Zagrebneva, Fomina et al., Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study, PloS One
Bulat, Situm, Azdajic, Likic, Potential role of IL-17 blocking agents in the treatment of severe COVID-19?, Br J Clin Pharmacol
Caldrer, Mazzi, Bernardi, Prato, Ronzoni et al., Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients, Front Immunol
Cecconi, Martinez-Vives, Vera, Olleros, Barrios et al., Efficacy of short-course colchicine treatment in hospitalized patients with moderate to severe COVID-19 pneumonia and hyperinflammation: a randomized clinical trial, Sci Rep
Choto, Makupe, Cakana, Sibanda, Mduluza, Excessive neutrophil recruitment promotes typical T-helper 17 responses in Coronavirus disease 2019 patients, PloS One
Core, R: A language and environment for statistical computing
Da, Roura-Piloto, Moral-Escudero, Bernal, Albendin-Iglesias et al., Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID), Int J Gen Med
Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease
Diaz, Orlandini, Castellana, Caccavo, Corral et al., Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial, JAMA Netw Open
Dupuis, Sirois, Rheaume, Nguyen, Clavet-Lanthier et al., Colchicine reduces lung injury in experimental acute respiratory distress syndrome, PloS One
Fajgenbaum, June, Cytokine Storm, N Engl J Med
Giannakodimos, Gkountana, Lykouras, Karkoulias, Tsakas, The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19, Curr Med Chem
Gurczynski, Moore, IL-17 in the lung: the good, the bad, and the ugly, Am J Physiol Lung Cell Mol Physiol
Hirano, IL-6 in inflammation, autoimmunity and cancer, Int Immunol
Jafrin, Aziz, Islam, Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies, Biomark Insights
Leforte, Hospital e Maternidade Christóvão da Gama
Lin, Fu, Yin, Li, Liu et al., ORF8 contributes to cytokine storm during SARS-CoV-2 infection by activating IL-17 pathway, iScience
Liu, Lu, Allan, Tang, Tetreault et al., Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A, J Inflamm Res
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open
Ma, Reynolds, Baker, Li, Benveniste et al., IL-17 enhancement of the IL-6 signaling cascade in astrocytes, J Immunol
Ma, Zhang, Ye, Chen, Yu et al., High Levels of Circulating IL-8 and Soluble IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19, Front Immunol
Mareev, Orlova, Plisyk, Pavlikova, Akopyan et al., Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiia
Maslennikov, Ivashkin, Vasilieva, Chipurik, Semikova et al., Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19), Eur Cytokine Netw
Mills, IL-17 and IL-17-producing cells in protection versus pathology, Nat Rev Immunol
Mulcahy, Hudson, Beggs, Reid, Roddam et al., High peripheral blood th17 percent associated with poor lung function in cystic fibrosis, PloS One
Pourdowlat, Saghafi, Mozafari, Sahebnasagh, Abedini et al., Efficacy and safety of colchicine treatment in patients with COVID-19: A prospective, multicenter, randomized clinical trial, Phytother Res: PTR
Pourgholaminejad, Pahlavanneshan, Basiri, COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges, Scand J Immunol
Qian, Liu, Hartupee, Altuntas, Gulen, The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease, Nat Immunol
Ravelli, Gigant, Curmi, Jourdain, Lachkar et al., Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain, Nature
Resende, Da Cruz Lage, Lobe, Medeiros, Costa et al., Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients -the BISHOP study, Infect Dis (Lond)
Ryzhakov, Lai, Blazek, To, Hussell et al., IL-17 boosts proinflammatory outcome of antiviral response in human cells, J Immunol
Sadeghi, Tahmasebi, Mahmood, Kuznetsova, Valizadeh et al., Th17 and Treg cells function in SARS-CoV2 patients compared with healthy controls, J Cell Physiol
Spolski, Li, Leonard, Biology and regulation of IL-2: from molecular mechanisms to human therapy, Nat Rev Immunol
Tardif, Bouabdallaoui, Allier, Gaudet, Shah et al., Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Van Eijk, Binkhorst, Bourgonje, Offringa, Mulder et al., COVID-19: immunopathology, pathophysiological mechanisms, and treatment options, J Pathol
Who, COVID-19 Clinical management: living guidance
Who, R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis
Yang, Masters, Fortner, Champagne, Yanguas-Casas et al., IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21-producing B helper CD8+ T cells, J Exp Med
Zhang, Wang, Li, Xi, Mao et al., Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients, Cell Mol Immunol
Zhu, Wang, Zhou, Wang, Ke et al., Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19, Exp Ther Med
